4.7 Article

Identification of peptidic substrates for the human kinase Myt1 using peptide microarrays

Journal

BIOORGANIC & MEDICINAL CHEMISTRY
Volume 23, Issue 15, Pages 4936-4942

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2015.05.021

Keywords

Peptide microarray; Myt1 kinase; Kinase substrate profiling; Fluorescence polarization assay

Funding

  1. European Regional Development Fund of the European Commission

Ask authors/readers for more resources

Myt1 kinase is a member of the Wee-kinase family involved in G2/M checkpoint regulation of the cell cycle. So far, no peptide substrate suitable for activity-based screening has been reported, hampering systematic development of Myt1 kinase inhibitors. Myt1 inhibitors had to be identified by using either binding assays or activity assays with expensive proteinous substrates. Here, a peptide microarray approach was used to identify peptidic Myt1 substrates. Wee1 kinase was profiled for comparison using the same technology. Myt1 hits from peptide microarray experiments were verified in solution by a fluorescence polarization assay and several peptide substrates derived from cellular proteins were identified. Subsequently, phosphorylation site determination was carried out by MS fragmentation studies and identified substrates were validated by kinase inhibitor profiling. (C) 2015 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity

Hany S. Ibrahim, Mohamed Abdelsalam, Yanira Zeyn, Matthes Zessin, Al-Hassan M. Mustafa, Marten A. Fischer, Patrik Zeyen, Ping Sun, Emre F. Buelbuel, Anita Vecchio, Frank Erdmann, Matthias Schmidt, Dina Robaa, Cyril Barinka, Christophe Romier, Mike Schutkowski, Oliver H. Kraemer, Wolfgang Sippl

Summary: In this study, a novel series of selective Class I HDAC inhibitors were synthesized and tested in vitro and in vivo. The most potent compound showed strong inhibitory effects and potential for treating various types of blood cancer cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Chemistry, Medicinal

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis

Ehab Ghazy, Mohamed Abdelsalam, Dina Robaa, Raymond J. Pierce, Wolfgang Sippl

Summary: This review focuses on the recent development of inhibitors for schistosome histone deacetylases, particularly inhibitors of Schistosoma mansoni histone deacetylase 8, which have shown promise for the treatment of schistosomiasis.

PHARMACEUTICALS (2022)

Article Biochemistry & Molecular Biology

Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors

Emre F. Bulbul, Jelena Melesina, Hany S. Ibrahim, Mohamed Abdelsalam, Anita Vecchio, Dina Robaa, Matthes Zessin, Mike Schutkowski, Wolfgang Sippl

Summary: In this study, a computational approach was used to predict the selectivity of inhibitors targeting HDAC1, HDAC2, and HDAC3. The developed binding free-energy models showed significant correlation between binding free energy and in vitro inhibitory activities, and successfully predicted the efficacy of newly designed inhibitors.

MOLECULES (2022)

Article Biochemistry & Molecular Biology

Small Changes Make the Difference for SIRT2: Two Different Binding Modes for 3-Arylmercapto-Acylated Lysine Derivatives

Diana Kalbas, Marat Meleshin, Sandra Liebscher, Matthes Zessin, Jelena Melesina, Cordelia Schiene-Fischer, Emre Fatih Bu''lbu''l, Frank Bordusa, Wolfgang Sippl, Mike Schutkowski

Summary: Sirtuins are protein deacylases involved in regulating metabolism, stress responses, and aging-related diseases. In this study, we synthesized and characterized 3-aryl-mercaptobutyrylated peptide derivatives as effective and selective Sirtuin 2 inhibitors. Our findings suggest that these inhibitors bind to the selectivity pocket of Sirtuin 2, inducing a rearrangement of the active site. Interestingly, 3-aryl-mercapto-nonalyl or palmitoyl derivatives exhibited a different binding mode, blocking both the hydrophobic channel and the nicotinamide pocket.

BIOCHEMISTRY (2022)

Article Biochemistry & Molecular Biology

Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity

Salma Darwish, Ehab Ghazy, Tino Heimburg, Daniel Herp, Patrik Zeyen, Rabia Salem-Altintas, Johannes Ridinger, Dina Robaa, Karin Schmidtkunz, Frank Erdmann, Matthias Schmidt, Christophe Romier, Manfred Jung, Ina Oehme, Wolfgang Sippl

Summary: This study developed proteolysis targeting chimeras (PROTACs) of HDAC8 based on potent and selective HDAC8 inhibitors. The selective HDAC8 PROTACs showed anti-neuroblastoma activity in cells, indicating their potential as targeted therapy for neuroblastoma.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Chemistry, Medicinal

Development and Validation of [3H]OF-NB1 for Preclinical Assessment of GluN1/2B Candidate Drugs

Hazem Ahmed, Livio Gisler, Nehal H. Elghazawy, Claudia Keller, Wolfgang Sippl, Steven H. Liang, Ahmed Haider, Simon M. Ametamey

Summary: GluN2B-enriched NMDARs are associated with several neurodegenerative and psychiatric diseases. In this study, a tritium-labeled form of OF-NB1 was developed as a selective GluN1/2B PET imaging agent. Competitive binding experiments and molecular simulations demonstrated the superior selectivity and performance of OF-NB1, making it a promising tool for screening potential GluN1/2B drug candidates.

PHARMACEUTICALS (2022)

Article Chemistry, Organic

N4-(2-Amino-4-fluorophenyl)-N1-(3-{2-[2-(3-{[2-(2,6-dioxo-3-piperidyl)-1,3-dioxoisoindolin-4-yl]amino}propoxy)ethoxy]ethoxy}propyl)terephthalamide

Mohamed Abdelsalam, Matthes Zessin, Matthias Schmidt, Mike Schutkowski, Wolfgang Sippl

Summary: The design and synthesis of a selective degrader of histone deacetylase-3 (HDAC3) using proteolysis targeting chimeras (PROTACs) is described in this study. The newly synthesized compound showed good inhibitory activity against HDAC3 but did not exhibit degradation for the targeted HDACs.

MOLBANK (2022)

Editorial Material Biochemistry & Molecular Biology

Editorial for Special Issue-Early-Stage Drug Discovery: Advances and Challenges

Wolfgang Sippl

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Chemistry, Medicinal

Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cells

Mohamed Abdelsalam, Mariia Zmyslia, Karin Schmidtkunz, Anita Vecchio, Sebastian Hilscher, Hany S. Ibrahim, Mike Schutkowski, Manfred Jung, Claudia Jessen-Trefzer, Wolfgang Sippl

Summary: In this study, a series of prodrugs for class I histone deacetylases (HDACs) were designed and synthesized using known selective HDAC inhibitors. Compound 6 showed the most potent inhibitory activity against nitroreductase (NTR)-transfected leukemic cells.

ARCHIV DER PHARMAZIE (2023)

Article Oncology

NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor

Ramy Ashry, Al-Hassan M. Mustafa, Kristin Hausmann, Michael Linnebacher, Susanne Strand, Wolfgang Sippl, Matthias Wirth, Oliver H. Kraemer

Summary: Tumors in the pancreas and colon are still a clinical challenge. Different gene expression profiles between cancer cells and normal cells can be targeted by drugs that modulate protein acetylation. KH16 is a novel compound that induces hyperacetylation, leading to cell death in tumor cells while sparing normal cells. It shows superior efficacy compared to clinically established drugs. Further studies can focus on KH16 and similar compounds for cancer therapy.

CANCERS (2023)

Article Chemistry, Medicinal

Application of Ligand- and Structure-Based Prediction Models for the Design of Alkylhydrazide-Based HDAC3 Inhibitors as Novel Anti-Cancer Compounds

Emre F. F. Buelbuel, Dina Robaa, Ping Sun, Fereshteh Mahmoudi, Jelena Melesina, Matthes Zessin, Mike Schutkowski, Wolfgang Sippl

Summary: This study analyzed different ligand-based and structure-based drug design techniques to predict the binding mode and inhibitory activity of recently developed alkylhydrazide HDAC inhibitors. Alkylhydrazides have shown promising effects in various cancer cell lines. The created models, including pharmacophore models and atom-based quantitative structure-activity relationship (QSAR) models, explain in vitro data well and were used to develop novel HDAC3 inhibitors.

PHARMACEUTICALS (2023)

Article Biology

Utilization of AlphaFold models for drug discovery: Feasibility and challenges. Histone deacetylase 11 as a case study

Fady Baselious, Dina Robaa, Wolfgang Sippl

Summary: In this study, we optimized the HDAC11 AlphaFold model by adding the catalytic zinc ion and successfully generated stable complexes for docking of selective inhibitors. The most reasonable pose was selected based on structural comparison, and the model explained the binding behavior of known HDAC11 inhibitors.

COMPUTERS IN BIOLOGY AND MEDICINE (2023)

Review Chemistry, Multidisciplinary

Challenges in natural product-based drug discovery assisted with in silico-based methods

Conrad V. Simoben, Smith B. Babiaka, Aurelien F. A. Moumbock, Cyril T. Namba-Nzanguim, Donatus Bekindaka Eni, Jose L. Medina-Franco, Stefan Guenther, Fidele Ntie-Kang, Wolfgang Sippl

Summary: The use of traditional medicine has a long history and is still relied upon by many, especially in developing or underprivileged communities. In silico-based methods have played a crucial role in drug discovery, particularly in identifying natural product-based candidates. However, there are challenges in identifying and proposing novel natural product-based hits.

RSC ADVANCES (2023)

No Data Available